

Michelle L Mierzwa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4274478/publications.pdf>

Version: 2024-02-01

42
papers

930
citations

471509

17
h-index

477307

29
g-index

42
all docs

42
docs citations

42
times ranked

1638
citing authors

#	ARTICLE	IF	CITATIONS
1	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 618-627.	0.8	156
2	Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life. <i>Radiotherapy and Oncology</i> , 2018, 126, 68-74.	0.6	74
3	Pattern of Marginal Local Failure in a Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy for Resectable and Borderline Resectable Pancreas Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 247-252.	1.3	62
4	Patient-reported financial toxicity and adverse medical consequences in head and neck cancer. <i>Oral Oncology</i> , 2020, 101, 104521.	1.5	48
5	Early Changes in Serial CBCT-Measured Parotid Gland Biomarkers Predict Chronic Xerostomia After Head and Neck Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1319-1329.	0.8	43
6	Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 350-359.	7.0	38
7	Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 1345-1352.	7.0	38
8	Recent Advances in Combined Modality Therapy. <i>Oncologist</i> , 2010, 15, 372-381.	3.7	37
9	Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 213-220.	4.2	36
10	Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. <i>Cancer</i> , 2020, 126, 354-362.	4.1	30
11	Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirus-associated oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 857-864.	2.0	28
12	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 151, 314-321.	0.6	24
13	Prospects and Challenges for Clinical Decision Support in the Era of Big Data. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-12.	2.1	23
14	Volumetric ¹⁸ F-FDG-PET parameters as predictors of locoregional failure in low-risk HPV-related oropharyngeal cancer after definitive chemoradiation therapy. <i>Head and Neck</i> , 2019, 41, 366-373.	2.0	23
15	Automatic recognition and analysis of metal streak artifacts in head and neck computed tomography for radiomics modeling. <i>Physics and Imaging in Radiation Oncology</i> , 2019, 10, 49-54.	2.9	23
16	Big data analysis of associations between patient reported outcomes, observer reported toxicities, and overall quality of life in head and neck cancer patients treated with radiation therapy. <i>Radiotherapy and Oncology</i> , 2019, 137, 167-174.	0.6	23
17	Quantification of liver function by linearization of a two-compartment model of gadoxetic acid uptake using dynamic contrast-enhanced magnetic resonance imaging. <i>NMR in Biomedicine</i> , 2018, 31, e3913.	2.8	21
18	Functional Adaptation in Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2019, 29, 236-244.	2.2	18

#	ARTICLE	IF	CITATIONS
19	Radiotherapy for Skin Cancers of the Face, Head, and Neck. <i>Facial Plastic Surgery Clinics of North America</i> , 2019, 27, 131-138.	1.5	18
20	Adaptive Boost Target Definition in High-Risk Head and Neck Cancer Based on Multi-imaging Risk Biomarkers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 969-977.	0.8	17
21	Predictive Values of MRI and PET Derived Quantitative Parameters for Patterns of Failure in Both p16+ and p16- High Risk Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1118.	2.8	17
22	Characterization of very late dysphagia after chemoradiation for oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 111, 104853.	1.5	15
23	Predicting late radiation-induced xerostomia with parotid gland PET biomarkers and dose metrics. <i>Radiotherapy and Oncology</i> , 2020, 148, 30-37.	0.6	15
24	Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation. <i>Oral Oncology</i> , 2021, 121, 105332.	1.5	15
25	Phosphorylation of TRIP13 at Y56 induces radiation resistance but sensitizes head and neck cancer to cetuximab. <i>Molecular Therapy</i> , 2022, 30, 468-484.	8.2	11
26	Pituitary Dysfunction after Radiation for Anterior Skull Base Malignancies: Incidence and Screening. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2020, 81, 075-081.	0.8	9
27	Patient Burden with Current Surveillance Paradigm and Factors Associated with Interest in Altered Surveillance for Early Stage HPV-Related Oropharyngeal Cancer. <i>Oncologist</i> , 2021, 26, 676-684.	3.7	8
28	Adjuvant radiation and cetuximab improves local control in head and neck cutaneous squamous cell carcinoma: Phase II study. <i>Head and Neck</i> , 2021, 43, 3408-3416.	2.0	8
29	Submandibular gland sparing when irradiating neck level IB in the treatment of oral squamous cell carcinoma. <i>Medical Dosimetry</i> , 2019, 44, 144-149.	0.9	7
30	Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin. <i>Head and Neck</i> , 2020, 42, 1728-1737.	2.0	6
31	Development and Assessment of a Model for Predicting Individualized Outcomes in Patients With Oropharyngeal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2120055.	5.9	6
32	Combination of a Big Data Analytics Resource System With an Artificial Intelligence Algorithm to Identify Clinically Actionable Radiation Dose Thresholds for Dysphagia in Head and Neck Patients. <i>Advances in Radiation Oncology</i> , 2020, 5, 1296-1304.	1.2	5
33	Early MRI Blood Volume Changes in Constrictor Muscles Correlate With Postradiation Dysphagia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 566-573.	0.8	5
34	Magnetic Resonance Guided Radiotherapy for Head and Neck Cancers. <i>Journal of Clinical Medicine</i> , 2022, 11, 1388.	2.4	5
35	Increased Pain Reporting by Head and Neck Cancer Patients at Radiation Oncology Consultation: A Quality of Life Analysis. <i>Laryngoscope</i> , 2021, 131, 326-332.	2.0	4
36	Financial Hardship in Patients With Head and Neck Cancer. <i>JCO Oncology Practice</i> , 2022, 18, e925-e937.	2.9	4

#	ARTICLE	IF	CITATIONS
37	Predictors of survival in patients undergoing oropharyngeal surgery for cancer recurrence after radiation therapy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 2085-2093.	1.6	3
38	Functional outcomes and tracheostomy dependence following salvage oropharyngeal surgery. <i>Oral Oncology</i> , 2021, 113, 105034.	1.5	3
39	Radiotherapy in Cutaneous Squamous Cell and Basal Cell Carcinoma. <i>Facial Plastic Surgery</i> , 2020, 36, 180-185.	0.9	2
40	Tumor-Infiltrating Lymphocytes in Patients With Advanced Laryngeal Cancer Undergoing Bioselection. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, , 019459982110137.	1.9	2
41	Imaging response assessment for predicting outcomes after bioselection chemotherapy in larynx cancer: A secondary analysis of two prospective trials. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 30-36.	1.7	0
42	Facilitating Automated Data Analytics Through Structured Head and Neck Oncology Tumor Board Documentation. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100168.	2.1	0